Navigation Links
ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
Date:12/17/2007

ADDISON, Texas, Dec. 17 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its nanoparticle aggregate patent.

This patent covers the underlying science behind the Company's nanoparticle aggregate technology; consequently, this is a very important asset in our patent portfolio.

Commenting on the issuance of the Notice of Allowance for the patent, Kerry P. Gray, President and Chief Executive Officer of ULURU, stated, "This Notice of Allowance is an important step in securing intellectual property protection for the range of products we anticipate developing from our nanoparticle aggregate technology. To further secure our patent position we have also filed additional patents to protect the wound care, breast implant and dermal filler applications of the technology."

On issuance, this patent will expire in 2022. The subsequently filed patent applications which broaden our patent position could extend the patent life for the wound care and breast implant product portfolios until the end of 2026.

Mr. Gray added, "The value of this family of patents is further enhanced by the substantial term remaining prior to patent expiration, which gives the company significant time to realize the full economic benefits of these important assets."

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-lo
'/>"/>

SOURCE ULURU Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Dynatronics Receives 180-Day NASDAQ Extension 2VidaOne 26apos 3Bs New iPhone Fitness Application Featured in App Store What 26apos 3Bs Hot List 61804 1VidaOne 26apos 3Bs New iPhone Fitness Application Featured in App Store What 26apos 3Bs Hot List 61804 2VidaOne 26apos 3Bs New iPhone Fitness Application Featured in App Store What 26apos 3Bs Hot List 61804 3New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 1New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 2New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 3New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 4New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 5New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 6New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 7New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 8New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 9New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U S Workforce According to Quest Diagnostics Drug T 61800 10Masimo to Present at the 21st Annual Piper Jaffray Health Care Conference 61796 1Masimo to Present at the 21st Annual Piper Jaffray Health Care Conference 61796 2